| Dr Colin M Goudelocke, MD | |
|
1514 Jefferson Hwy, New Orleans, LA 70121 | |
| (504) 842-4083 | |
| (504) 842-6271 |
| Full Name | Dr Colin M Goudelocke |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 20 Years |
| Location | 1514 Jefferson Hwy, New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164631149 | NPI | - | NPPES |
| 07096 | Medicaid | LA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Clinic Foundation | New orleans, LA | Hospital |
| Ochsner Medical Center-kenner | Kenner, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
A team of experts from the School's Trauma Epidemiology and Injury Prevention Research Center has received two grants to expand the program, which focuses on interventions to assist older drivers who may be at risk for a crash due to age-related health impairments.
› Verified 9 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
A team of experts from the School's Trauma Epidemiology and Injury Prevention Research Center has received two grants to expand the program, which focuses on interventions to assist older drivers who may be at risk for a crash due to age-related health impairments.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Colin M Goudelocke, MD 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Dr Colin M Goudelocke, MD 1514 Jefferson Hwy, New Orleans, LA 70121 Ph: (504) 842-4083 |
News Archive
Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer. In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, Breastcancer.org is making public Dr. Weiss' ODAC letter in its entirety.
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
A team of experts from the School's Trauma Epidemiology and Injury Prevention Research Center has received two grants to expand the program, which focuses on interventions to assist older drivers who may be at risk for a crash due to age-related health impairments.
› Verified 9 days ago
Carrie Aline Stewart, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave, New Orleans, LA 70112 Phone: 256-658-1406 | |
Dr. Harold A Fuselier, MD Urology Medicare: Medicare Enrolled Practice Location: 2820 Napoleon Ave, Suite 890, New Orleans, LA 70115 Phone: 504-412-1366 Fax: 504-412-1367 | |
Dr. Nathan Samuel Wexler, M.D. Urology Medicare: Medicare Enrolled Practice Location: 6050 Annunciation St, New Orleans, LA 70118 Phone: 504-897-3088 Fax: 504-891-1326 | |
Dr. David C Benson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2000 Canal St Fl 5, New Orleans, LA 70112 Phone: 504-702-4333 | |
Dr. Raju Thomas, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1415 Tulane Ave, Urology Clinic, New Orleans, LA 70112 Phone: 504-988-2300 Fax: 504-988-7655 | |
Louis Spencer Krane, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1430 Tulane Ave, New Orleans, LA 70112 Phone: 504-988-2750 | |
Dr. Aaron D Martin, M.D., M.P.H Urology Medicare: Accepting Medicare Assignments Practice Location: 200 Henry Clay Ave, New Orleans, LA 70118 Phone: 504-896-9233 Fax: 504-896-9861 |